Sud Shivani, Weiner Ashley A, Wang Andrew Z, Gupta Gaorav P, Shen Colette J
Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC.
Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, University of North Carolina Hospitals, Chapel Hill, NC.
Semin Radiat Oncol. 2021 Oct;31(4):309-323. doi: 10.1016/j.semradonc.2021.03.008.
Human papillomavirus (HPV) causes the majority of oropharyngeal, cervical, and anal cancers, among others. These HPV-associated cancers cause substantial morbidity and mortality despite ongoing vaccination efforts. Aside from the earliest stage tumors, chemoradiation is used to treat most HPV-associated cancers across disease sites. Response rates are variable, and opportunities to improve oncologic control and reduce toxicity remain. HPV malignancies share multiple commonalities in oncogenesis and tumor biology that may inform personalized methods of screening, diagnosis, treatment and surveillance. In this review we discuss the current literature and identify promising molecular targets, prognostic and predictive clinical factors and biomarkers in HPV-associated oropharyngeal, cervical and anal cancer.
人乳头瘤病毒（HPV）会引发大多数口咽癌、宫颈癌和肛门癌等。尽管一直在进行疫苗接种工作，但这些与HPV相关的癌症仍会导致大量发病和死亡。除了最早期的肿瘤外，放化疗被用于治疗不同疾病部位的大多数与HPV相关的癌症。缓解率各不相同，改善肿瘤控制和降低毒性的机会仍然存在。HPV恶性肿瘤在肿瘤发生和肿瘤生物学方面有多个共同特征，这可能为个性化的筛查、诊断、治疗和监测方法提供依据。在本综述中，我们讨论了当前的文献，并确定了与HPV相关的口咽癌、宫颈癌和肛门癌中有前景的分子靶点、预后和预测性临床因素及生物标志物。
